Clinical Pearls for Retinal Surgery

BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY EDMUND G. BROWN JR., GOVERNOR

STATE BOARD OF OPTOMETRY 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov

Continuing Education Course Approval Checklist

Title: Clinical Pearls for Retinal Surgery

Provider Name: Orange County Optometric Society c/o Dr. Rachelle Lin, OD

Completed Application Open to all optometrists? Yes No Maintain record agreement? Yes No

Detailed Course Description PowerPoint and/or other presentation materials Advertising (optional) CV for EACH course instructor License Verification for each course instructor

Disciplinary History? Yes No

The Committee decided to have this course brought back to another meeting with answers to specific questions, prior to making a decision.

www.optometry

Dr. Rachelle Lin, OD, MS, FAAO OCOS 2015-2016 Education Chair OCOS 2016 President Elect Cell: 909-525-6737 Direct Email: [email protected]

8/20/2016

To whom it may concern,

I am writing in response to questions regarding the CE Clinical Pearls for Retinal Surgery that was offered Feb. 8th, 2016 at an Orange County Optometric Society meeting.

Was there any dialogue during the surgical procedure (did surgeon talk) or was it strictly observation? Yes, there was dialogue during the surgical procedure. The surgeon described the

procedures as they were shown, pointing out relevant information such as ocular diagnosis, surgical materials used, surgical equipment used, specialized techniques utilized, and potential surgery complications and contraindications. The surgeon also discussed relevant information for other slide images that were shown. For clarification, the CE is not comprised of simply a slideshow or videos. The surgeons giving the CE are discussing the relevant information while the images and videos are being shown.

How much (percentage) was about the operating room procedures and instruments, and how much of the course was information about the surgical procedures? Dr. Timothy Yous portion of the lecture discussed both operating room procedures and

instruments as well as surgical procedures. The time was approximately split evenly between the two for his portion.

Was it televised to help everyone see clearly, and if sohow? Yes, the CE is presented in a format so that the attendees can clearly see and hear what

is being presented. We utilize a laptop computer connected to a projector. The presentations and videos were projected onto a large projector screen against the meeting room wall. Room lighting could also be adjusted as needed to maximize visibility of images shown. We were also able to arrange the seats in half crescent configuration around the round tables so that all attendees would have direct view of the screen. Laser pointers are also used as needed to highlight specific points in images. A speaker and microphone were also used. OCOS organizes events to provide high quality CE and we make effort to ensure the presentations are accessible for attendees.

Was there a commentary and/or discussion about the procedure afterwards? Yes, there is commentary and/or discussion about the procedures, images, and cases

shown. This commentary can occur before, during, and/or after the material is visually presented. Questions from attendees were also allowed.

1

mailto:[email protected]

--

J

. BUSINESS, CONSUMER SERVICES. AND HOUSING AGENCY GOVERNOR EDMUND G. BROWN JR,

:lil\ STATE BOARD OF OPTOMETRY.U 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 P (916) 575~7170 F (916)575-7292 www.optometry.ca.gov

0PTOMiTRY

CONTINUING EDUCATION COURSE APPROVAL

_$_5_0_M_~in_d_at_o_ry___l APPLICATION .__ Pursuant to California Code of Regulations (CCR} 1536, the Board will approve continuing education {CE} courses after

receiving the applicable fee, the requested information oelow ana it nas5eerrnetermlrre-d-th-atthe-coarse-me-ets-criteria specified in CCR 1536(9).

In addition to the information requested below, please attach a copy of the course schedule and topical outline of the subject matter. Applications must be subm.itted 45 days prior to the course presentation date.

Please type or print clearly. Course Title Course Presentation Date

Course Provider Contact Information

Provider Name (00~ CJ:v..V\'t'j Q~vV\lrtV\C.. ?Oc.Ae.rt,;t~} KO\.ckl~ L{v\ CJ

(First) {Last} (Middle) Provider Mailing Address

Street Z.S:J ~ Y(J'vioG. Ct~ City ~l~O'V\ State~ Zip q2s~i l!Ph' o\.

Provider Email Address . r.i.c~lle.. l'1 \I\ @@YrA.l\, (.Cl\/\!\ ' .

Wilt the proposed course be open to an California licensed optometrists? JiiQYES ONO

Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires. for a period of at least three years ~YES ONO fromthe date of course presentation?

Course Instructor Information Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. I h . d ' fft ere are more instructors in the course, please provi e the requested Jnformat1on on a separate sheet o paper. Instructor Name

yQlA~.. r~::t. t - - (last) {Middle)-

License Number &'%of>?..S License Type CJ:j ()\"':::f.':i\c..1.c...16. ~ )\A~OY' G I

Phone Number Gl:iJ '1 T2 --%~ 3"2. Email Address +~O'l,A@. QC.v-eft"'-0\ V\Q.."t. I declare under penalty ofperjury under the laws of the State ofCalifornia that all the information submitted on this form and on any accompan ing attachments submitted is true and correct.

25/t/2-0\.f:.

Form CE~o1, Rev. 2(16

http:www.optometry.ca.gov

Orange County Optometric Society

Dr. Rachelle Lin, OD, MS, FAAO OCOS 2016 Education Chair

OCOS 2016 President Elect , Cell: 909-525-6737

Direct Email: [email protected]

5/5/2016

To whom it may concern,

Regarding the 45 days for Request for Approval of CE Courses submission for the Feb. 8th , 2016 CE event for Orange County Optometric Society:

Final[zed speakers and presentations were dependent on surgery scheduling on the day of the event. Furthermore, OCOS board had to wait for the presenters to submit their finalized presentations before a complete CE application package could be mailed. One presentation was submitted to OCOS board very late as changes were still made to it after the 45 day cutoff.

All attempts are made to submit CE approval application packages as soon as possible. Unfortunately, since we occasionally use outside guest speakers presenting new or updated content, it can be difficult to collect the finalized presentations far in advance of the scheduled CE event date.

Please feel free to contact me directlywith any questions.

Sincerely,

~c~l(e_ o6'V\ Rachelle Lin, OD

Rache!!e Lin, OD, MS, FMO Assistant Professor Mary Ann Kever!ine Walls Low Vision Center Marsha!! B. Ketchum University 2575 Yorba Linda Blvd. I Fullerton, CA 92831-1699 714.992.7825 I [email protected]

3

mailto:[email protected]:[email protected]

Course Title: Clinical Pearls for Retinal Surgery

Instructor Name: Dr. Timothy You, MD

Course Description and Objectives:

This lecture includes historical information regarding operating rooms and surgical procedures leading up to

modern developments for safe and successful surgeries. Operating room procedures and equipment are

discussed, including equipment management and sterile techniques. Operating room equipment modifications

necessary for complicated retinal surgeries are also covered. Considerations for scleral buckling and use of

intraoperative OCT are also discussed.

This lecture serves as an introduction to modern retinal surgery for optometrists, and is especially useful for

optometrists referring patients for retinal surgery and working in hospital settings and co-management sites.

Lecture objectives include increasing understanding of retinal surgical procedures. Information from this lecture

also facilitates patient education regarding surgical referrals.

4

5

:,)/ _,

RSVP by 2/1/16 at www.ocos.org $30 for OCOS/COA Members

$45 for N'qn~Members 1

,$55 At"the I)qdr . .

OCUS MEETING

MONDAY, FEB. BTH

@ MA.GGlANO'S LlTTLE ITALY, 3333 BRISTOL ST, COSTA MESA 92626

RECI8TRAT10N BEGINS 6:30 PM DINNER & CE FROM. 7 :00-9:00 PM

2 Hours of CE

"Clinical Pearls for Retinal Surgery" by OC Retina

Featuring:

Timot}:iy You, MD Sanford Chen, MD Raj Rathod, MD

E . en7Chang, MD 1'vfillie Liu, OD Margaret Yu, OD

13

Wall Chart

- -------------

3/14/16

,,

- -I

---------------------- -

1 !Bl Retinal Detachment EUGENE CHANG MD

FEBRUARY 10, 2015

ORANGE COUNTY RETINA

2 !i;;sJl Types of Retinal Detachment ..,.Rhegmatogenous

..,.Tractional

..,.Exudative/serous

3 l~l Rhegmatogenous

4 IBl Tractional .

s !G;Jl Exudative/Serous

6 l1:1l Posterior Vitreous Detachment

7 l~l Signs and Symptoms of Retinal Detachment

..,.Flashing lights

..,.New Floaters

..,.A shadow in the periphery of your field of vision

..,.A gray curtain moving across your field of vision

s !~l Types of Surgery ..,.Pneumatic retinoplexy

..,.Scleral buckle

..,.Vitrectomy

9 !E:Jl Pneumatic Retinoplexy ..,.Introduced by Dr. Hilton and Grizzard and extensively

investigated by Dr. Tornambe ..,. Initially recommended in the superior 8 clock hours ..,.Tornambe published experiences in 302 eyes, in which a

single injection attachment rate of 68% and a final attachment rate after reoperations of 95%

..,.Complications were: new retinal breaks (7-33% ), cystoid macula edema (0-8%), subretinal gas (0-4%), PVR (3-13%), cataract form9tion 1-20%) and epiretinal membranes (2-11 % )

10 !Bl Sciera! Buckling

..,.Described by Custodis in Germany (1949), Schepens and

Lincoff in the US

..,._Single surgery reattachment rate of 81-88% in uncomplicated

cases

16

1

3/14/16

..,.Procedure changes the refraction of the patient - myopic shift(1 mm lengthening of the is about 3 diopters)

..,.Complications: infection of the episcleral device, conjunctiva! erosion, extrusion of the implant, motility problems, double vision and retinal folds

..,.MediCare data - US 1997 38%; 2007 9%

11 li;;;gJ Sciera! Buckle & Vitrectomy Surgery 12 l~J Primary Pars Plana Vitrectomy

..,.Machemer popularized this technique in the early 1970s

.,.Single case success rate of 64-100%

.,.Risk of vitrectomy - cataract progression in phakic eyes, iatrogenic holes, remnants of perfluorcarbon liquids (pre and SR), overfill with gas resulting in post op pressure spike, positioning problems with intraocular lens after cataract surgery

13 ~ 14 l~H So what's the best procedure?

.,.Mehta et al - retrospective study- phakic patients reattachment rates - 83% in vitrectomy alone group vs. 97% in the vitrectomy and encircling band group, in psuedophakic patients no difference was found

.,.Schall et al - reattachment rate of 63% for pneumatic retinoplexy, 86% for SB, 90% for ppV alone, 94% for combination of SB and ppV

.,.Azad et al - did NOT find a statically significant difference between SB and ppV with respect to retinal reattachment rates (80.6% for SB vs 80% for vitrectomy)

..,.The Retinal Detachment Study - single operation reattachment rate was 82% for SB and 7 4 %for PR

1s ~ THE SPR .,.Sciera! buckling vs. primary vitrectomy in RRD study group

25 centers in 5 countries - 265 pseudophakic patients and 416 phakic patients

..,.primary reattachment rate of 63.6% in SB and 63.8% with vitrectomy ..,.,n complicated phakic patients - scleral l;)uckling is better

17

2

3/14/16

than vitrectomy ..,._In psuedophakic patients - vitrectomy is better ..,._Combined vitrectomy and scleral buckling leads to better

results than vitrectomy alone in pseudophakic eyes 16 [GJI Trends

..,._According to Medicare data - 80% more vitrectomies are performed in the US relative to 1997, while.scleral buckling is down by 70%, more than 70% of primary retinal detachment cases are currently treated with vitrectomy

..,._Germany - 40% scleral buckle, 60% vitrectomy

..,._UK - vitrectomy accounts for 80-90% of the cases

..,._PVR - proliferative vitreoretinopathy ..,._-If you fail with vitrectomy as a primary procedure, PVR will

develop more quickly than in buckle cases. Vitrectomy is less forgiving and failure will turn your case in to a more severe case compared to buckling

18

3

Retinal Tears

Millie Liu, OD

19

Rule #1 - Always check for Shafers sign!

20

Clinical Pearls

Look up & down to stir up the vitreous

Unsure if Shafers or debris? Compare the vitreous in the other eye!

You will still see Shafers in those who have had previous tears

**More than 90% of all retinal breaks can be caught with this skill!

22

Br J Ophthalmol 2000;84:1264-1268 doi:10.1136/bjo.84.11.1264

Predictive value of Vitreous Pigment & symptomatology

In 200 eyes presenting with an acute PVD: 25 were found to have an associated retinal break, 23 of which were Shafer positive.

In 115 eyes presenting for retinal detachment repair: 111 had an associated PVD and were found to be Shafer positive.

23

Symptoms

- If pts are VERY symptomatic with unilateral machine-gun flashes.. refer anyways unless you are scleral depressing.

- The IOP in the suspect eye might be lower than its fellow eye also.

24

Main Risk Factors

- Older age (5th-7th decade)

- myopia (>6D) - Diabetes - direct blunt trauma - family history of retinal tears or detachments - previous RT/RD - intraocular inflammation (uveitis) - Previous eye surgery such as CE.

Based on symptoms + shafers sign + high risk factors, you can already make the decision in most caseswhether or not to refer before even starting your fundus exam!

25

Retinal Detachments

Impress your retina specialist- Find the tear! Is it Mac-on or off?

There is a saying When you find one tear, look for the other!

Why is finding the tears important?

26

Wheres the tear?

27

Flashes & Floaters

64yo Caucasian male presents with flashes and floaters OD. - Onset 1 day ago. VA: - OD- 20/80- PH 20/50- OS- 20/20 IOP:

J1 J8

- 18/19 OD/OS Ant Seg: - PCIOL OU Post Seg: - NO shafers sign OU - Weiss ring OD - 2 dot hemorrhages on ON OD - No tears/detachments, attached 360 OU

* No systemic conditions 28

ACUTE PVD

- Optic Disc Hemorrhage OD: Most likely secondary to slight vessel avulsion from vitreous separation.

- RTC in 6 weeks - Pt ed on signs & symptoms of RT/RD and RTC STAT

29

Questions?

[email protected]

30


Does lightning strike twice?

Margret Yu, O.D.

31

78 year old Asian male

CC: decreased vision OS last 3-5 days

VA: OD: CF 3 OS: 20/800

History of Polypoidal Choroidal Vasculopathy OU

32

OD Fundus Image

33

OS Fundus Image

34

OS Fundus Image

35

Submacular Hemorrhage

36

Visual Damage

Mechanisms Iron Hemosiderin Fibrin Clot retraction Physical separation of photoreceptors from RPE

Duration of hemorrhage Predicts visual recovery 21 days: no improvement in vision

37

Visual Damage

38

Treatment

PDT Anti-VEGF Pneumatic

displacement Surgery

39

Pneumatic Displacement

Topical anesthesic Intravitreal injection

Sulfur hexafluoride (SF6) Perfluoropropane (C3F8)

Face down positioning

Ideal candidate Duration Location Compliance

40

Tissue Plasminogen Activator

Protein involved in breakdown of blood clots Facilitate clot liquefaction and pneumatic displacement

Many small case series demonstrate that the addition of of intravitrealt-PA can be beneficial

Additional volume of t-PA aqueous tap

Prone head positioning

The additive role of t-PA has been debated. One study did not find a beneficial or harmful effect Other reports suggest that t-PA can cause retinal toxicity Some investigators question whether intravitreal t-PA crosses the subretinal space

41

Submacular hemorrhage with t-PA

42

78 year old Asian male

43

References

http://www.retinalphysician.com/articleview er.aspx?articleID=100437

http://www.reviewofophthalmology.com/cont ent/d/retina/c/46006/

44

http://www.reviewofophthalmology.com/conthttp://www.retinalphysician.com/articleview

Dr. Chen was not able to attend that night and did not speak. He was listed as one of the 6 doctors who work at OC Retina.

45

CURRICULUM VITAE

Rajiv R. Rathod, M.D., M.B.A.Fellow, American Academy of Ophthalmology

Mailing/Contact Address:

Orange County Retina Medical Group

1200 North Tustin Avenue, Suite 140

Santa Ana, California 92705

714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Locations

Orange County Retina Medical GroupPhysician/Surgeon

Since July 2012

1200 North Tustin Avenue 1200 North Tustin Avenue 24022 Calle de la Plata 320 Superior Avenue 333 W. Bastanchury Road 31451 Rancho Viejo Road

Suite 140 Suite 100 Suite 475 Suite 160 Suite 200 Suite 101

Santa Ana, CA 92705 Santa Ana, CA 92705 Laguna Hills, CA 92653 Newport Beach, CA 92663 Fullerton, CA 92835 San Juan Capistrano, CA 92675

714-972-8432 714-972-8432 949-581-3618 949-646-3242 714-451-0801 949-496-0611

EDUCATION AND TRAINING

Vitreo-Retinal FellowshipUniversity of IllinoisChicago, Illinois; 2010-2012

ResidencyChief Resident, OphthalmologyWashington University School of MedicineSt. Louis, Missouri; 2009-2010

OphthalmologyWashington University School of Medicine / Barnes-Jewish HospitalSt. Louis, Missouri; 2006-2009

Internship in MedicineSanta Clara Valley Medical Center Transitional InternshipStanford University School of MedicineSan Jose, California; 2005-2006

Medical School Medical Doctorate Vanderbilt University School of MedicineNashville, Tennessee; 2000-2005

Graduate Master of Business Administration Owen Graduate School of ManagementVanderbilt UniversityNashville, Tennessee; 2003-2005

46Updated 10Sep2014.MC R.R. Rathod, MD, MBA Page 1 of 6

http:10Sep2014.MC

UndergraduateBachelor of Science, Biological SciencesStanford UniversityStanford, California; 1995-1999

BOARD CERTIFICATION

American Board of Ophthalmology, Diplomate 2012United States Medical Licensing Examination, Diplomate 2006

MEDICAL LICENSURE

California, issued 2012Illinois, through 7/31/14Missouri, through 1/31/11

HONORS

2011 Fellow of the Year Award, University of Illinois at Chicago 2010 Golden Apple Best Teacher Award, Washington University 2009 Mat Guirgis Pediatric Ophthalmology & Strabismus Award: Outstanding Resident, Washington

University 2009 Ron Burde Award (dedication to teaching and patient care), Washington University 2008 Career Physician Chief Resident Program Competition Winner 2005 Beta Gamma Sigma, Vanderbilt Chapter 2004 Tulane Business Plan Competition, Second Place 2001 Microbes and Defense Society, Vanderbilt University 2001 Top Spear Award (top student in physiology course), Vanderbilt University

PROFESSIONAL ORGANIZATIONS

American Academy of Ophthalmology American Medical Association Chicago Ophthalmological Society Missouri Society of Eye Physicians and Surgeons St. Louis Ophthalmological Society

HOSPITAL/SURGERY CENTER AFFILIATIONS

2012 Present Anaheim Regional Medical Center, Anaheim, California 2012 Present Barranca Surgery Center, Irvine, California 2012 Present Children's Hospital of Orange County, Orange, California 2012 Present Childrens Hospital at Mission, Mission Viejo, California 2012 Present Hoag Memorial Hospital Presbyterian, Newport Beach, California 2012 Present Pacifica Hills Surgery Center, Laguna Hills, California 2012 Present St. Joseph Hospital, Orange, California 2012 Present St. Jude Medical Center, Fullerton, California 2012 Present Western Medical Center, Santa Ana, California


http:10Sep2014.MC

CLINICAL RESEARCH

Six years of experience, prior to July 2012, in conducting research in ophthalmology-related topics includingendophthalmitis, vitreoretinal surgery, retinal detachment repair, and sickle cell retinopathy.

01. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2012-PresentSub-Investigator. A multicenter, masked, randomized, comparator-controlled study evaluation

Isonep (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD

02. Alimera Sciences, Protocol C-01-11-008, FAME Extension Study; 2012-2013Sub-Investigator. An open-label, multicenter, extension study of the safety and utility of the new

inserter of Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien in subjects with DME

03. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III; 2012-2013Sub-Investigator. A prospective, multi-center, randomized, double-masked, positive controlled, clinicaltrial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmicsuspension (1%) in patients with non-infectious anterior segment uveitis

04. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II; 2012-2013Sub-Investigator. An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema

05. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD-A), Phase III; 2012-PresentSub-Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy ofgevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis

06. Pfizer, Protocol B1181003-1050, Phase II; 2012-2013Sub-Investigator. A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dosestudy to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration

07. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD-C), Phase III, 2012-PresentSub-Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitiscurrently controlled with systemic treatment

08. Regeneron, Protocol VGFTe-AMD-1124 (RE-VIEW), Phase IV; 2012-PresentSub-Investigator. Rigorous evaluation of vision and safety with intravitreal afliberecept injection dosedevery 8 weeks over 2 years in neovascular AMD

09. Merck, Protocol MK8931017 (SCH 900931, P07738), Phase 2/3, Collaborative Study; 2012-PresentOphthalmology Investigator. A randomized, placebo controlled, parallel-group, double blind efficacyand safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease

10. Allergan, Protocol GMA-OZU-13-598, Retropective Registry; 2013-PresentSub-Investigator. A retrospective data collection study in patients receiving anti-VEGF injections forretinal vein occlusion or diabetic macular edema


http:10Sep2014.MC

11. Opththotech, Protocol OPH1003 (ECLIPSE), Phase III; 2013-PresentSub-Investigator. A double-masked, controlled trial to establish the safety and efficacy of intravitreousadministration of FovistaTM (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

12. Allergan, Protocol GMA-OZU-13-598 (ECHO), Retrospective Registry; 2013-PresentSub-Investigator. A retrospective data collection study in patients receiving anti-VEGF injections forretinal vein occlusion or diabetic macular edema

13. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II; 2014-PresentPrincipal Investigator. A phase 2, randomized, active-controlled, double-masked, multicenter study toassess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, asmonotherapy or adjunctive to Ranibizumab, in subjects with diabetic macular edema

14. Xoma, Protocol X052132 (EYEGUARD-E), Phase III; 2014-Present Sub-Investigator. An open-label, non-randomized, single-arm, roll-over study to continue dosing ofGevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfullycompleted either the X052130 or the X052131 study

15. Merck, Protocol MK8931-019, Phase III, Collaborative Study; 2014-PresentOphthalmology Investigator. A phase III, randomized, placebo-controlled, parallel-group, double blindclinical trial to study the efficacy and safety of MK8931 (SCH900931) in subjects with amnestic mild cognitive impairment due to Alzheimer's Disease (Prodromal AD)

16. National Eye Institute, SCORE2, Phase III; 2014-PresentSub-Investigator. A multicenter, prospective, randomized non-inferiority trial of eyes with macularedema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weekswith intravitreal afliberecept every 4 weeks

17. Allergan, Protocol #150998-004 (PALM), Phase II; 2014-PresentPrincipal Investigator. Evaluation of Abicipar Pegol (AGN-150998) in patients with decreased vision dueto diabetic macular edema

18. Thrombogenics, Protocol #TG-MV-018 (ORBIT), Prospective Registry, Phase IV; 2014-PresentSub-Investigator. Ocriplasmin Research to Better Inform Treatment

19. Thrombogenics, Protocol #TG-MV-022 (OZONE), Retrospective Registry, Phase IV, 2014-PresentSub-Investigator. Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study

20. Allergan, Protocol #GMA-US-EYE-0272 (REINFORCE), Prospective Registry, Phase IV; 2014-PresentSub-Investigator. The Ozurdex Diabetic Macular Edema Patient Registry

21. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), Phase III; 2014-PresentSub-Investigator. A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration


http:10Sep2014.MC

BIBLIOGRAPHY

ARTICLES 01. Rathod RR, Mieler WF. An update on the management of intraocular foreign bodies.Retinal Physician; April 2011.

PUBLISHED ABSTRACTS/POSTER PRESENTATIONS01. Rathod RR, Shen DJ, Wang MX. Relationship between stromal ablation depth and

hyperopic shift after 6 mm phototherapeutic keratectomy using VISX Star Excimer Laser.Investigative Ophthalmology and Visual Science 2002;43:E-Abstract 159.

02. Rathod RR, Wang MX, Cohen I. Effects of posterior corneal refractive power changeon LASIK; June 2002. American Society of Cataract and Refractive Surgery

03. Rathod RR, Khanifar A, Kammer JA. Incidence of glaucoma after repeat penetratingkeratoplasty. Investigative Ophthalmology and Visual Science 2005;46: E-Abstract 130.

04. Rathod RR, Apte RS, Blinder KJ. Safety and outcomes of 25-gauge transconjunctivalvitreoretinal surgery. Investigative Ophthalmology and Visual Science 2008;49: E-Abstract 6002.

05. Rathod RR, Rao PK. Incidence of intraocular infection in the setting of systemic fungal infection. Investigative Ophthalmology and Visual Science 2009;50: E-Abstract 3554.

06. Rathod RR, Lim JI. Outcomes of retinal detachment repair with relaxing retinectomies in cases ofsevere proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science 2011;52: E-Abstract 6170.

07. Rathod RR, Lim JI. The utility of relaxing retinectomies in repair of recurrent retinal detachmentswith severe proliferative vitreoretinopathy. Presented as poster at American Society of Retina SpecialistsMeeting; August 2011.

08. You TT, Huang CX, Chen S, Maggiano JM, Rathod RR, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. Submitted Aug2014 to Retinal Cases & Brief

Reports.

PRESENTATIONS 01. The Role of Submacular Surgery in the Treatment of Choroidal Neovascular Membranes in POHS

Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; January 31, 2007

02. Posterior Reversible Encephalopathy SyndromeWashington University Department of Ophthalmology and Visual Sciences, Grand Rounds; February 21,2007

03. Functional Visual Loss Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; March 27,2007

04. Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-InfectiousAnterior Segment Uveitis: Phase I/II DataAnaheim, California; October 3, 2012


http:10Sep2014.MC

05. Retina Updates: Case PresentationsRetina Care Symposium, Costa Mesa, California; December 5, 2013

06. Complications of Cataract Surgery South Coast Eye Care Center, Laguna Hills, California; March 14, 2014

07. Updates on AMDJCAHPO Regional Meeting, Costa Mesa, California; March 15, 2014

08. Maternally Inherited Diabetes and DeafnessRetina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20,2014

09. Plaquenil ScreeningRetina Care for Rheumatologists, Santa Ana, California; June 4, 2014

10. Plaquenil ScreeningNVISION Annual Summer Symposium Program, Anaheim, California; June 22, 2014

11. Diabetic Macular Edema: Case Studies Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine,California; September 10, 2014

COMMUNITY INVOLVEMENT

Mobile Eye Care Clinic for the Homeless, Illumination Foundation, Santa Ana Amory, Santa Ana, CA; January 18, 2014

Mobile Eye Care Clinic for the Homeless, Illumination Foundation, Saddelback Memorial Care Hospital, San Clemente, CA; November 4, 2012

LANGUAGES

Medical Spanish, Gujarati


http:10Sep2014.MC

CURRICULUM VITAE ==

TIMOTHY T. YOU, M.D. Fellow, American Academy of Ophthalmology




Santa Ana, California 92705

714-972-8432



Physician/Surgeon/Partner

Since 3/1/2005

1200 North Tustin Avenue Suite 140 Santa Ana, CA 92705 1200 North Tustin A venue Suite 100 Santa Ana, CA 92705 24022 Calle de la Plata Suite 475 Laguna Hills, CA 92653 320 Superior A venue Suite 160 Newport Beach, CA 92663 333 W. Bastanchury Road Suite 200 Fullerton, CA 92835 31451 Rancho Viejo Road Suite 101 San Juan Capistrano, CA 92675

7 /2002-2/2005 Rhode Island Eye Institute, Providence, Rhode Island 7 /1999-6/2002 Pacific Clear Vision Institute, Eugene, Oregon


Vitreo-Retinal Fellowship Massachusetts Eye and Ear Infirmary Harvard Medical School, Boston, Massachusetts, 1997-1999

Thomas Heed Ophthalmic Fellow, 1997-98 American Ophthalmological Society, Herman Knapp Fellow, 1998-99

Research Fellowships Penn Medical Scholars Anatomic Pathology Fellowship Department of Pathology & Laboratory Medicine Hospital of the University of Pennsylvania, 1991-1992

Children's Hospital of Los Angeles University of Southern California, Doheny Eye Institute Medical Student Fellowship in Pediatric Ophthalmology, 1989

Residency in Ophthalmology Massachusetts Eye and Ear Infirmary Harvard Medical School, Boston, Massachusetts, 1994-1997

Internship in Medicine VA Medical Center, Sepulveda, California University of California, Los Angeles, 1993-1994

Medical School Medical Doctorate University of Pennsylvania School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, 1988-1993

714-972-8432 714-972-8432 949-581-3618 949-646-3242 714-451-0801 949-496-0611

52Revised: 3 !Dec2013.MC T. You,MD Page I of 12

http:Dec2013.MC

---,)

------------------,-- .....___,_

Undergraduate Education Bachelor of Science in Biology with distinction in major & cum laude Yale College, New Haven, Connecticut, 1984-1988

Lab Assistant, Yale School of Medicine, Department of Microbiology, 1987

PROFESSIONAL POSITIONS

2013-Present Clinical Rotation Preceptor, Southern California College,of Ophthalmology, Fullerton, California

2012-Present Preceptor and Site Coordinator, Western University Health Sciences, Pomona, California

2012-Present Chief, Department of Ophthalmology, Children's Hospital of Orange County, Orange, California

2009-Present Advisor, Clinical Institute , St. Joseph Hospital, Orange, California

2010-2012 Member, Planning Committee, Children's Hospital of Orange County Tower, Orange, California

. 2006-Present Expert Witness, Medical Board of California

2005-Present Medical Reviewer, MES Group

2003-2005 Assistant Clinical Professor in Ophthalmology, Brown Medical School, Providence, Rhode Island

2000-Present Medical Reviewer, Advanced Medical Group

1997-1999 Assistant Staff, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts

MEDICAL LICENSES

American Board of Ophthalmology, Diplomate, (Board Certified) in 1999 Exam score 95th percentile

American Board of Ophthalmology, Diplomate, (Recertification) in 2009 Maintanence of Certification

Diplomat National Board of Medical Examiners, since 1994

Medical Board of California, since 1993

53

Revised: 3 !Dec2013.MC T. You,MD Page 2 of 12

http:Dec2013.MC

HOSPITAL AFFILIATIONS

3/1/2005 - Present

3/1/2005 - Present

3/1/2005 - Present

3/1/2005 - Present

3/1/2005 - Present

3/1/2005 - Present

3/1/2005 -Present

Anaheim Regional Medical Center, Anaheim, California

Children's Hospital at Mission, Mission Viejo, California

Children's Hospital of Orange County, Orange, California

t Hoag Memorial Hospital Presbyterian, Newport Beach, California

St. Joseph Hospital, Orange, California

Western Medical Center, Anaheim, California

Western Medical Center, Santa Ana, California

HONORS AND AWARDS

2003 Brown Medical School Award for Excellence in Teaching

1999 Fellow of the Year for Massachusetts Eye and Ear for Excellence in Teaching

1999 Fellow Award at Paul Chandler Lecture for Resident Teaching

1997 STORZ Ophthalmic Instrument Design Contest for Modified Phaco-Chopper

1994-1991 Bill Raskob Foundation Award

1993 History of Medicine Prize, The Stigma ofAtomic Bomb Disease

1992 History of Medicine Prize, A Short History ofEgyptian Military Ophthalmia

1989 Whanki Essay Contest, The Perfect Painting, second place

1988 Summer Research Internship, Taejon Research Institute, South Korea

1985 Jostens' Scholarship

1985 Elks Club Western-Division Scholarship

1985 Soroptomist Club Scholarship

1985 Orange County Medical Association Scholarship

1984-1988 Mission Community Hospital Auxiliary Scholarship

1982-1984 American Academy of Sciences Junior Scientist, University of Southern California/University of California at Irvine

54Revised: 31Dec2013.MC T. You,MD Page 3 of 12

http:31Dec2013.MC

.. '-~-PROFESSIONAL SOCIETY MEMBERSHIPS

American Academy of Ophthalmology, Fellow

American Society of Retina Specialists (The Vitreous Society)

Association for Research in Vision and Ophthalmology

California Association of Eye Physicians and Surgeons

California Medical Association

California Scholarship Federation

Orange County Society of.Ophthalmology

Orange County Medical Association

Oregon Medical Association

Society of Heed Fellows

Society of Penn Medical Scholars

Western Retina Study Club

CLINICAL RESEARCH

01. Genetech, Inc., Protocol #FVF2598g (Marina), Phase IIIb, 2003-2005 Sub-Investigator. A multicenter, randomized, double masked, sham injection-controlled study of the safety and efficacy ofrhuFab V2 in subjects with neovascular AMD who have minimally classic or occult lesion

02. Eyetech Pharmaceuticals, Protocol #EOP1004, Phase II/III, 2005-2005 Sub-Investigator. A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections ofEYEOOJ ( antiVEGF pegylated aptamer )"in patients with exudative AMD

03. Alcon Research, Ltd., Protocol C-01-99, Phase III, 2005-2005 Sub-Investigator. A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety ofanecortave treatment relative to Visudyne for AMD.

04. OxiGENE, Inc., Protocol MMD-213, Phase III, 2005-2006 Sub-Investigator. A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy ofcombretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia.

05. Diabetic Retinopathy Clinical Research Network(DRCR)/National Eye Institute, Protocol B, 2005-2009 Sub-Investigator. A randomized trial comparing intravitreal corticosteroids and laser photocoagulation forDME.

06. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III, 2005-2009 Sub-Investigator. A_necortave Acetate B_isk Reduction Irial (AART): An evaluation ofefficacy and safety ofposterior juxtascleral administrations ofanecortave acetate for depot suspension ( 15 mg or 30 mg) versus sham administration in patients ( enrolled in study "A" or study "B ") at risk for developing sight-threatening CNV due to exudative AMD.

07. National Eye Institute, SCORE, 2005-2009 Sub-Investigator. The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection( s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO.

Revised: 31Dec20!3.MC T. 55

You,MD Page 4 of 12

http:31Dec20!3.MC

08. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV, Collaborative Study, 2005-2006 Sub-Investigator. A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction.

09. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III, 2005-2007 Sub-Investigator. A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 with exudative AMD.

10. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV, 2005-2007 Sub-Investigator. A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD.

11. Novartis, Protocol CBPD952E2202 (Veritas), Phase IIIB, 2005-2007 Principal Investigator. A 24-month randomized, double-masked, sham controlled, multicenter study comparing PDT with verteporfin (Visudyne) plus two different dose regimens ofintravitreal triamcinolone acetonide ( 1 mg and 4 mg) versus Visudyne plus intravitreal pegaptnanib (Macugen) in patients with subfoveal CNV secondary to AMD.

12. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV, 2006-2008 Principal Investigator. An open label, multicenter trial ofmaintenance intravitreous injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement.

13. Novartis, Protocol #CBPD952A2308 (Denali), Phase IIIB, 2006-2010 Principal Investigator. A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizimub (Lucentis) versus ranibizumub (Lucentis) monotherapy in patients with subfoveal CNV secondary to AMD.

14. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III, 2006-2011 Sub-Investigator. Eluocinolone A,.cetonide in Diabetic Macular f;.dema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy ofASI001A 0.5ug!day and ASI-001B 0.2 uglday fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur).

15. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III, 2006-2011 Sub-Investigator. CLinical !;;_valuation ofA,.nti-angiogenesis in the Retina - lntravitreal I.rial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability ofrepeated doses ofintravitreal VEGF Trap in subjects with neovascular AMD.

16. Opko, Protocol ACU-301 (COBALT), Phase III, 2007-2009 Sub-Investigator. COmbining B.evasirinib and L.ucentis T.herapy (COBALT): A randomized, doublemasked, parallel-assignment study of intravitreal bevasirinib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections ofLucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD.

56

Revised: 31Dec2013 .MC T. You, MD Page 5 of 12

17. Allergan, Protocol 206207-012, Phase III, 2007~2010_-Sub-Investigator. A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posteriorsegment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment ofsubjects with diffuse DME.

18. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III, 2007-2010

Sub-Investigator. A :;,afety and efficacy study ofVitreosolve for ophthalmic intravitreal injection for

inducing posterior vitreous detachment in subjects with NPDR.

19. Merck & Co., Protocol 007-01 , Collaborative Study, 2008-2009 Ophthalmology Investigator. A safety follow-up study ofpatients previously exposed to MK-0634 ( a beta-3 receptor antagonist developed for the treatment ofoveractive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, doseranging study ofL-000796568 in postmenopausal women with OAB.

20. Allergan, Protocol 206207-019-00, Phase II , 2008-2010 Sub-Investigator. A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis in the treatment ofpatients CNV secondary to AMD.

21. Ophthotech Corp., Protocol OPH3000, Phase I, 2008-2010 Sub-Investigator. An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile ofmultiple intravitreous injections ofvolociximab ( a5/31 integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD.

22. Regeneron, Protocol VGFT-OD-0706 (Da Vinci), Phase III, 2008-2011 Sub-Investigator. A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME.

23. NEI/Tufts Medical Center, The Family Study of Macular Degeneration, 2009-2010 The goal is to evaluate genetic and non-genetic riskfactorsfor AMD

24. Allergan, Protocol 206207-018-00, Phase II, 2008 - 2010 Sub-Investigator. A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME.

25. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study, 2009-2011 Sub-Investigator. A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety ofa new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy.

26. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study, 2010-2011 Sub-Investigator. A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety ofEN3324 (Axomadol) in subjects with moderate to severe chronic low back pain.

27. GlaxoSmithKline, Protocol MD 7110852, Phase IIB, 2009-2012 Principal Investigator. A dose-'ranging study ofpazopanib eye drops vs. ranibizumab intravitreal injections for the treatment ofneovascular AMD.

Revised: 31Dec2013.MC T. You,MD 57

Page 6 of 12

http:31Dec2013.MC

28. Genentech, Protocol FVF4579g (HARBOR), Phase IIt, 2009-2012 Sub-Investigator. A double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety ofO.5 mg and 2 .0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD.

29. Lux Biosciences, Inc., Protocol LX211-11, Phase III, 2011-2013 Sub-Investigator. A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety ofVoclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-"ltlveitis.

30. Lpath, Protocol LT1009-0ph-003 (NEXUS), Phase IIA, 2011-Present Sub-Investigator. A multicenter, masked, randomized, comparator-controlled study evaluation lsonep (sonepcizumab [LTI009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment ofsubjects with choroidal neovascularization secondary to AMD.

31. Alimera, Protocol C-01-11-008, Extension Study, 2011-2013 Sub-Investigator. An open-label, multicenter, extension study of the safety and utility of the new inserter oflluvien ( Fluocinolone Acetonide lntravitreal Insert) 0 .J 9mg and the safety of!luvien in subjects with DME.

32. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013 Sub-Investigator. A prospective, multi-center, randomized, double-musked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension ( 1 %) in patients with non-infectious anterior segment uveitis

33. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-2013 Sub-Investigator. An open-label dose escalation study ofPF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety ofPF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema

34. Xoma, Protocol X052130/CL3-78989-005, Phase III, 2012-Present Principal Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy ofgevokizumab in the treatement ofactive non-infectious intermediate, posteriqr, or pan-uveitis

35. Pfizer, Protocol Bl 181003-1050, Phase II, 2012-2013 Sub-Investigator. A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics ofRN6G (PF04382923) in subjects with geographic atrophy secondary to age-related macular degeneration

36. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD-C), Phase III, 2012-Present Principal Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy ofgevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment

37. Regeneron Protocol VGFTe-AMD-1124 ((RE-VIEW), Phase IV, 2012-Present Sub-Investigator. Rigorous evaluation ofvision and safety with intravitreal afliberecept injection dosed every 8 weeks over 2 years in neovascular AMD

38. Merck Protocol MK8931-017 (SCH 900931, P07738), Phase 2/3, Collaborative Study, 2012-Present Ophthalmology Investigator. A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial ofMK-8931 in subjects with mild to moderate Alzheimer's disease

58Revised: 31Dec20I3.MC T. You, MD Page 7 of 12

http:31Dec20I3.MC

39. Ophthotech OPH1003, Phase III, 2013-Present Sub-Investigator. A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration ofFovista (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular macular degeneration

ABSTRACTS

01. Wong CG, You TT, Ghosen C, Ton L, You L, Burke J, Wheeler L. Experimental CNVin Cynomologous Monkey after Sustained Release ofVEGF & bFGF'within the Suprachoroidal Space. Association for Research in Vision and Ophthalmology Meeting; May 2011. Abstract

02. Wong CG, You TT, Carvalho RAP. Natural history of progressive experimental CNV in the rabbit after sustained release of both VEGF and bFGF within the supra-choroidal space. Association for Research in Vision and Ophthalmology Meeting, May 2009. Abstract

03. Wong CG, Bruice TC, You TT. Experimental CNV after transcleral implantation ofVEGF/bFGFimplant within the suprachoroidal space for defining potential long-term synergistic actions of ranibizumab (Lucentis) with small low-cost molecules in ameliorating wet AMD. Association for Research in Vision and Ophthalmology Meeting, May 2008. Abstract

04. You TT, Wong CG, Fedoruk T, Bonakdar M. Comparison of Lucentis and Avastin in the suprachoridal VEGF/bFGF-implant rabbit CNV model provides a potential standardized pre-clinical approach in the rational development of more effective QSAR-based drugs, sustained release formulations, and drug delivery systems for ameliorating AMD. Association for Research in Vision and Ophthalmology Meeting, 2007. Abstract

05. Gupta G, Donahue JP, Andorsky S, You TT. Profile of the retina by optical coherence tomography in the pediatric age group. Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida; May 1, 2005. Abstract

06. Gupta G, and You T. Vitreous Hemorrhage in age-related macular degeneration. New England Ophthalmological Society, Boston, Massachusetts; May 2004. Abstract

07. You TT and Itturiaga J. "The Range of Abnormalities in Drosophila l (1 )ts-726 after High Temperature Shock Treatments." California Academy of Science Meeting, Los Angeles, California; 1984. Abstract

08. You T and Itturiaga J. "Variations in Bristle Pattern After High Temperature Treatment in Drosophila melanogaster." American Academy of Science Meeting, New York, New York; 1984. Abstract

Revised: 31Dec2013.MC T. You, 59

MD Page 8 of 12

http:31Dec2013.MC

~~~~-----

PAPElfS AND PUBLICATIONS

01. You TT, Youn DW, Chen S, Alexandrescu B, Casiano ME, Maggiano JM. Intraocular penetration by acupuncture needle. (submitted for publication, Retina)

02. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori PC, Adamis AP. Transscleral delivery ofbioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000 Apr; 41.(5):1186-91.

03. Arroyo JG, You TT, Bossi KE. Illuminated lens fixator for bimanual pars plana lensectomy. Ophthalmic Surg Lasers 2001 Sep-Oct;32(5):438-40.

04. Rumeldt S, You TT, Remulla HD, Rubin PAD, Jakobiec FA. Prepartum mixed type cavernouscapillary hemangioma arising in nevus flammeus. Ophthalmology 1999;106:1219-22.

05. You TT and Power W. Choroidal detachments and uveal effusion syndrome. In: Principles and Praxis of Ophthalmology Vol. 2. Albert DM & Jacobiec F (eds). Saunders. Philadelphia. 1999;13381351. , .

06. You TT and JG. Arroyo. Surgical approaches to managing the dislocated crystalline lens. Int Ophthalmol Clinics 1999;39:1-12.

07. You TT and Kaiser PK, Netland PA, Jakobiec FA. Neurothekeoma palpebrae: a rare nerve sheath tumor arising in the eyelid. Ophthal Plast Reconstr Surg. 1999;6:448-9.

08. You TT and Young LHY. Retinal manifestations of gastrointestinal disorders. Int Ophthalmol Clinics 1998;38:197-220.

09. You TT, et al. Corneal Abrasion Patching Study Group. A study of topical nonsteroidal antiinflammatory drops and no pressure patching in the treatment of corneal abrasions. Ophthalmol 1997; 104: 1353-59.

10. You, TT arid Pavan-Langston D. Chronic unilateral keratitis in a young man. Dig J Ophthalmol 1995 October 25;Vol. 1. Issue 2.

11. You, TT and Dohlman CH. Progressive corneal opacification and arthropathy. Dig J Ophthalmol 1995 August 12;Vol. 1, Issue 1.

12. You TT, Choi JC, Partington MA, Whital,

..

POSTERS & PRESENTATIONS

01. Updates in Retina Care: Macular Degeneration and Implantable Miniature Telescope Course Director. Retina Care Symposium, Costa Mesa, California; December 5, 2013.

02. Healthcare Invited speaker. Third Annual Yorba Linda High School Career Day, Yorba Linda, CA; November 13, 2013. .

03. Updates in Macular Degeneration

Invited speaker (JCAPHO). South Coast Eye Center, Laguna Hills, California; November 8, 2013.

04. Cataract Surgery: Retinal Perils, Risks and Complications. Invited speaker. NVision Centers, Costa Mesa, California; August 22, 2013.

05. Retinopathy ofPrematurity and Eye Care for Infants Invited speaker. Anaheim Regional Medical Center, Anaheim, California; February 21, 2013.

06. Healthcare Invited speaker. Second Annual Yorba Linda High School Career Day, California; November 1, 2012.

07. Jontopheretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis: Phase III Data. Anaheim, California; October 3, 2012.

-08. Updates in Age-Related Macular Degeneration

Invited speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2012.

09. Update on Retinal Venocclusive Diseases Guest speaker (JCAPHO). South Coast Eye Medical Centers, Laguna Hills, California; March 9, 2012.

10. Healthcare Invited speaker. First Annual Yorba Linda High School Career Day, California; November 8, 2011.

11. Management of Ophthalmic Emergencies Invited speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2011.

12. Retinal Disease Management Invited Speaker, Fuentes de Gracia Hospital Grand Rounds. Chimaltenango, Guatemala; March 2011.

13. Diabetes and the Eye Invited Speaker. St. Joseph's Hospital, Orange, California; February 26, 2011.

14. Overcoming Retina Hurdles to 20/20 Vision/or Your Patients Invited Speaker. Orange County Optometric Society, Western Medical Center, California; August 8, 2010

15. Diabetes and the Eye Invited Speaker. St. Joseph's Diabetes Day Conference, St. Joseph Medical Center, Orange, California; February 26, 2010.

l 6. Retinopathy ofPrematurity and Other Ocular Anomalies Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; October 27, 2009.

17. Co-Moderator, Day of Ophthalmology. St. Joseph's Hospital, Orange, California; October 3, 2009.

61Revised: 31Dec2013.MC T. You, MD Page 10 of 12

http:31Dec2013.MC

18.. Retinopathy ofPrematurity and Neonatal Eye Diseases

Invited Speaker. Children's Hospital of Orange at Mission Viejo, California; September 28, 2009.

I9. Retinopathy ofPrematurity and Neonatal Eye Diseases

Invited Speaker. Department of Neonatology, Childrens' Hospital of Orange County, California;

July 13, 2009.

20. Updates in Ophthalmic Care Invited Speaker, fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala; July 2009.

21. Updates on New Treatment for Retinal Diseases Invited Speaker. TLC Annual Symposium, Anaheim, California; June 7, 2009.

22. Macular Degeneration Invited Speaker, Foundation for Fighting Blindness. Low Vision Symposium, Southern California College of Optometry, Fullerton, California; May 9, 2009.

23. The Refractive Surgery Retinal Evaluation: Pearls and Pitfalls Invited Speaker. TLC, Newport Beach, California; April 22, 2009.

24. Retinal Disease Updat,e Invited Speaker. Fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala. August 8, 2008.

25. Emerging Treatment Strategies for Exudative AMD. Novartis Speaker Program. Costa Mesa, California; March 12, 2008.

26. Emerging Treatment Strategies for Exudative AMD. Novartis Speaker Program. Newport Beach, California; February 20 2008.

27. Retinopathy ofPrematurity and Other Ocular Anomalies Invited Speaker. Children's Hospital of Orange at Mission. Mission Viejo, California; February 20, 2007.

28. Toxoplasma Uveitis Invited Speaker, Continuing Medical Education Lecture. Children's Hospital of Orange County, Orange, California; October 23. 2006

29. Retinopathy ofPrematurity Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; March 14, 2006.

30. Retinopathy ofPrematurity and Neonatal Eye Diseases Invited Speaker. Hoag Presbyterian Hospital, Newport Beach, California; July 12, 2005.

31. The Great Debates: Controversies in Retinal Disease 2005 Invited Speaker, Medical Education Seminar. University of California, Irvine, Beckman Laser Center, Irvine, California; March 26, 2005.

32. Pediatrics Case Conference Invited Speaker. Rhode Island Hospital, Providence, Rhode Island; January 20, 2003.

33. Advances in Retina Rhode Island Eye Institute, Providence, Rhode Island; 2002.

62Revised: 31Dec2013.MC T. You, MD Page 11 of 12

http:31Dec2013.MC

. -=-=~-=--=--34. Posterior Segment

Posterior Segment Rounds, Central Oregon Optometric Association, Redmond, Oregon; 2001.

35. Medicine 2000 Oregon Society of Medical Assisting Conference, Eugene, Oregon; 2000.

36. Retinal Diagnoses Pacific Northwest Conference, Bend, Oregon; 2000.

i

37. Retinal Surgery throughout the Ages Lane County Optometric Society Meeting, Eugene, Oregon; 1999.'

38. You TT and Arroyo JG. Surgical approaches to dislocated lenses. Annual Fellows' Conference, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1998.

39. You TT and Young LHY. "Retinal Manifestations of Gastrointestinal Disorders." Biennial Residents' Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1997.

40. You TT, R.N. Hogan, C.S. Foster, C.H. Dohlman. "Corneal Injury in Stevens-Johnson Syndrome." Contact Lens Association of Ophthalmologists Meeting, Las Vegas, Nevada; 1997. Poster

41. You TT, Hogan RN, Yuhan KR, Foster CS, C.H. Dohlman. "A Clinicohistopathologic Study of Cornea in Erythema Multiforme Major." Academy of Ophthalmology Meeting, Chicago, Illinois; 1996. Poster

42. You TT, Hogan RN, Foster CS, Dohlman CH. "Keratopathy in Stevens-Johnson Syndrome: Histopathologic Study of Diseased Cornea." Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida; 1996. Poster

43. You TT and Pavan-Langston D. "Sterile Inflammatory Reactions in Herpes Keratitis." Biennial Residents' Day Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1995.

44. Navon S, You TT, Chynn EW. "Eye Examination." NPACE Skills Building Seminar,Pramingham, Massachusetts; 1995.

45. Cognitive Decision Making -A Computer Based Model Society of General Internal Medicine Meeting, Washington, DC; 1994.

46. You TT, Partington MA, Whitaker LA. "Congenital Torticollis and Plagiocephaly: Clinically Frequent Association." 51st American Cleft Palate and Craniofacial Association Conference, Toronto, Canada; 1994.

47. Bacterial Utilization ofDissolved Organic Matter in a Natural, Oligotrophic Aquatic System California Academy of Science Meeting, Los Angeles, California; 1981.

63Revised: 31Dec20I3.MC T. You,MD Page 12 of 12

http:31Dec20I3.MC

CURRICULUM VITAE

Eugene Chang, M.D., M.B.A. Medical License #A77825




Santa Ana, California 92705,

714-972-8432


Orange County Retina Medical Group Physician/Surgeon

Since December 2013

Locations 1200 North Tustin Avenue Suite 140 Santa Ana, CA 92705 714-972-8432 1200 North Tustin Avenue Suite 100 Santa Ana, CA 92705 714-972-8432 24022 Calle de la Plata Suite 475 Laguna Hills, CA 92653 949-581-3618 320 Superior A venue Suite 160 Newport Beach, CA 92663 949-646-3242 333 W. Bastanchury Road Suite 200 Fullerton, CA 92835 714-451-0801 31451 Rancho Viejo Road Suite 101 San Juan Capistrano, CA 92675 949-496-0611


Vitreo-Retinal Fellowship Rush University Medical Center/Illinois Retina Associates Chicago, Illinois; 2004-2006

Residency, Ophthalmology California Pacific Medical Center San Francisco, California; 2001-2004

Residency, Internal Medicine (preliminary) University of California, San Francisco, School of Medicine/Fresno-Central San Joaquin Valley Medical Education Program Fresno, California; 2000-2001

Medical School/Graduate Medical Doctorate/Master of Business Administration Tufts University School of Medicine/Tufts University Boston, Massachusetts; 1996 - 2000

Undergraduate Bachelor of Arts in Political Science Brown University Providence, Rhode Island; 1992-1996

64

BOARD CERTIFICATION

American Board of Ophthalmology

MEDICAL LICENSURE

Illinois, issued 2004 ,

California, issued 2002

HONORS

1994 Recipient of The Brown University Undergraduate Teaching & Research Assistantship

PROFESSIONAL MEMBERSHIPS

American Academy of Ophthalmology American Society of Retinal Specialists

PROFESSIONAL/WORK EXPERIENCE

2006 - 2013 Vitreoretinal Surgeon Kaiser Permanente, Oakland, California

1996 - 1998 Medical Education Review Committee Representative

1995 - 1996 Teaching Assistant Department of Biology, Brown University, Providence, Rhode Island

Summer 1997 Intern Dyax Corporation, Cambridge, Massachusetts

Summer 1995 Research Fellow Center for International.and Security Studies, Taiwan Institute of Economic Research, Taipei, Taiwan

HOSPITAL STAFF AFFILIATIONS

2014 - Present Anaheim Regional Hospital, Anaheim, California

2014 - Present Children's Hospital of Orange County, Orange, California

2014 - Present Children's Hospital of Orange County, Mission Viejo, California

2014 - Present St. Joseph Hospital, Orange, California

65

RESEARCH

01. Clinical Research in Glaucoma, 1999-2000 Joe S. Schuman, M .D, Department of Ophthalmology, New England Eye_Center, Boston,_ Massachusetts - Researched the relationship between glaucoma status and macular thickness as measured with Optical

Coherence Tomography

02. Research Assistant, 1994-1995

Robert F. Valentini, Ph,D., Brown University, Department of Orth'opaedics, Providence, Rhode Island - Assayed drug delivery system in rat and human cell lines - Devised experiments to quantify the amount of drugs released into target cells

03. Research Assistant, 1994-1995 Hugh S. Keeping, Ph.D., Brown University, Department of Orthopaedics, Providence, Rhode Island

- Managed research projects with grant awarded by Brown Univers.ity - Studied the role of bone morphogenetic proteins in the pathogenesis of tumors metastases to bone. - Developed quantitative approaches to determine cytokine interactions during prostate cancer progression.

CLINICAL RESEARCH

01. Ophthotech, Protocol OPHI003 (ECLIPSE), Phase III; 2014-Present Sub-Investigator. A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration ofFovista (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subjoveal neovascular macular degeneration

02. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II; 2014-2015 Sub-Investigator. A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy ofdaily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to Ranibizumab, in subjects with diabetic macular edema

03. Xoma, Protocol X052132 (EYEGUARD-E), Phase III; 2014-2015 Sub-Investigator. An open-label, non-randomized, single-arm, roll-over study to continue dosing of Gevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfully completed either the X052130 or the X052131 study

04. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD -A), Phase III; 2014-2015 Sub-Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment ofactive non-infectious intermediate, posterior, or pan-uveitis

05. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD -C), Phase III; 2014-2015 Sub-Investigator. A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment

06. National Eye Institute, SCORE2, Phase III; 2014-2016 Sub-Investigator. A multicenter, prospective, randomized non-inferiority trial of eyes with_ macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal ajliberecept every 4 weeks

66

07. Lpath, Protocol LT1009-0ph-003 (NEXUS), Phase IIA; 2014-2015 Sub-Investigator. A multicenter, masked, randomized, comparator-controlled study evaluation oflsonep

(sonepcizumab [LT! 009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone-for the treatment ofsubjects witkchoroida.l neovascularization secondary to agerelated macular degeneration

08. Allergan, Protocol #150998-004 (PALM), Phase II; 2014-2015 Sub-Irrvestigator. Evauation ofAbicipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema

09. Thrombo genies, Protocol #TG-MV -018 (ORBIT), Prospective Registry; Phase IV, 2014-Present Sub-Investigator. Ocriplasmin Research to Better Inform Treatment

10. Thrombogenics, Protocol #TG-MV-022 (OZONE), Retrospective Registry, Phase IV; 2014-2015 Sub-Investigator. Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study

11. Allergan, Protocol #GMA-US-EYE-0272 (REINFORCE), Prospective Registry, Phase IV; 2014-Present Sub-Investigator. The Ozurdex Diabetic Macular Edema Patient Registry

12. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), Phase III; 2014-Present Sub-Investigator. A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration

13. Xoma, Protocol X052133 (EYEGUARD-US), Phase III; 2015-2015 Sub-Investigator. A randomized-withdrawal, double-masked, placebo-controlled study of the efficacy and safety of gevokizumab in treating subjects with Beh9et's disease uveitis

14. Allegro Ophthalmics, Protocol DME-202B (DEL MAR), Phase II; 2015-2015 Sub-Investigator. A phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy ofLuminate (ALG-1001) as compared to Avastin@ and focal laser photocoagulation in the treatment ofdiabetic macular edema

15. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-Present Sub-Investigator. A phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hl-conl in patients with choroidal neovascularization secondary to age-related macular degeneration

16. Bayer, Protocol BAY 73-4506/15984 (DREAM), Phase Ila/IIB; 2015-2015 Sub-Investigator. A combined phase Ila/Ilb study of the efficacy, safety and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naive subjects with neovascular age-related macular degeneration

17. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present Sub-Investigator. A multicenter, randomized, double-masked, parallel-group, active-controlled study evaluating the safety and efficacyof abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration

18. Ophthotech, Protocol OPH1004, Phase III; 2015-Present Sub-Investigator. A phase 3, randomized, double-masked, controlled tiral to establish the safety and efficacy of intravitreous administration ofFovista ( anit PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

19. Ophthotech, Protocol OPH1005 Phase III; 2015-Present Principal Investigator. A 24 month, phase 2a, open label, safety study ofFovista ( anti-PDGF-BB pegylated aptamer) regimen administered in combination with anti-VEGF therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy

67

20. Ophthotech, Protocol OPH1006 Phase III; 2015-Present Principal Investigator. Effect ofanti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study ofAvastin, Lucentis, or Eylea ( anti-VEGF therapy) administered in combination with Fovista ( anti-PDGF BB pegylated aptamer)

21. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-Present Sub-Investigator. A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in paitents with neovascular age-related macular degeneration

t

22. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-Present , Sub-Investigator. A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema

23. Alcon, Protocol RTH258-C001 (HA WK), Phase III; 2015-Present Sub-Investigator. A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety ofRTH258 versus afliberecept in subjects with neovascular age-related macular degeneration

24. Clearside Biomedical Protocol #CLSlOOl-301 (PEACHTREE), Phase III; 2015-Present Sub-Investigator. A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis

25. Genentech Protocol #GX28228 (LADDER), Phase II; 2016-Present Sub-Investigator. A phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibuzumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular agerelated macular degeneration

26. EyeGate Pharma Protocol #EGP-437-006 Phase III; 2016-Present Sub-Investigator. A prospective, multicenter, randomized, double-masked, positive-controlled, phase 3 clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution compared to prednisolone acetate ophthalmic suspension ( 1 %) in patients with non-infectious anterior segment uveitis

68

BIBLIOGRAPHY

01. Chang E, Chow DR, Packo KH, Olivier S. Our experience with 25-gauge vitrectomy; its efficacy, efficiency and a look at procedure-based outcomes. American Society of Retina Specialists, 23 rd Annual Meeting, Montreal, Canada; 2005

02. Chang E, Luckie A, Ai E, Ahmed I. Ophthalmic Manifestation ofHIV chapter in HIV InSite Knowledge

Base. UCSF; 2005

03. Chang E. Wi-Fi 101, Techniques in Ophthalmology, December 2004, 171-172.

04. Chang E. Flat Panel Display Technologies, Techniques in Ophthalmology, June 2005, 106-08.

05. Keeping HS, Chang G, Angert L, Chang E, Ehrlich MG, Glantz L, Narayan P, Dahiya R. Interleukin modulation ofprostatic bone morphogenetic protein expression in primary tumors and bone metastases. 41st Annual Meeting, Orthopaedic Research Society.

06. Keeping, HS, Chang G, Angert L, Chang E, Ehrlich MG, Glantz L. Interleukin modulation ofprostatic bone morphogenetic protein expression in primary tumor and bone metastases. 2nd Annual Rhode Island Hospital/Women and Infants Hospital Research Poster Day.

07. You TT, Huang CX, Chen S, Maggiano JM, Rathod RR, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. (Submitted Aug2014, Retinal Cases & Brief Reports)

PRESENTATIONS/LECTURES

01. Good visual acuity following proliferative vitreoretinopathy Barkan Society Meeting, San Francisco, California; 2003

02. Our experience with 25-gauge vitrectomy: its efficacy, efficiency, and a look at procedure-basrd outcomes American Society of Retina Specialists' 23rd Annual Meeting, Montreal, Canada; 2005

03. Fluorescein Angiography, Indocyanine Green Angiography and Optical Coherence Testing 14th Annual Rush Medical College of Ophthalmology Clinical Review Course; 2005

04. Diagnostic Testing Retina Care Symposium, Costa Mesa, California; December 5, 2013

05. Case Presentation. Punctate Inner Choroidopathy Retina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20, 2014

06. Gevokizumab for Patients with Uveitis Retina Care for Rheumatologists, Santa Ana, California; June 4, 2014

07. Diabetic Macular Edema: Case Studies Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine, California; September 10, 2014

LANGUAGES

Mandarin

69

-,CURRICULUM VITAE

Millie Mei Liu, O.D.

Mailing/Contact Address: Orange County Retina Medical Group 1200 North Tustin Avenue, Suite 140

Santa Ana, California 92705 714-972-8432


Orange County Retina Medical Group Optometrist

Since 9/1/2014

1200 North Tustin Avenue 1200 North Tustin Avenue 24022 Calle de la Plata 320 Superior Avenue 333 W. Bastanchury Road 31451 Rancho Viejo Road

Suite 140 Suite 100 Suite 475 Suite 160 Suite 200 Suite 101

Santa Ana, CA 92705 Santa Ana, CA 92705 Laguna Hills, CA 92653 Newport Beach, CA 92663 Fullerton, CA 92835 San Juan Capistrano, CA 92675

714-972-8432 714-972-8432 949-581-3618 949-646-3242 714-451-0801 949-496~0611


Optometry School Doctorate of Optometry Western University of Health Sciences, College of Optometry Pomona, California 2010- 2014

Undergraduate Bachelor of Science, Physiology and Neuroscience Minor in Psychology University of California, San Diego San Diego, California 2006- 2010

BOARD CERTIFICATION National Board of Examiners in Optometry

LICENSURE California, Issued 2014

70

Page 1of5

j~=---- -- ------- ====-----------__-_~~

I

I

I

I

I

J

i i

PROFESSIONAL BACKGROUND 1-~=~========~~===========:_____2015 - Present Consultant to the ACOE (Accreditation Council on Optometric Education).

2014 - Present Clinical Rotation Precept01; Western University Health Sciences, Pomona, California

2014 - Present Optometrist, Orange County Retina Medical Group, Orange County, California

Spring 2014 41h year Optometry Intern, Orange County Retina Medical Group, Orange County, California

Winter 2014 41h year Optometry Intern, Hellerstein and Brenner Vision Center, P.C., Denver, Colorado

Fall 2013 411, year Optometry Intern, La Jolla Lasik/ Prestera Eye Medical group, San Diego, California

Summer 2013 41h year Optometry Intern, Bay Pines VA Hospital, Bay Pines, Florida

Fall 2011 2nd year Optometry Iniern, Kawata Eric J OD Inc, Anaheim, California

2011- 2013 Tutor, Oxford Tutoring, Inland Empire, California

2007 -2010 Laboratory Assistant, Roger Tsien (Nobel Prize Laureate) Laboratory, San Diego, California

2007 - 2010 Intern, Family Vision Care- Gary Sneag, O.D., San Diego, California

2007 - 2010 Intern, Optometric Vision Development Center - Claude Valenti, OD, San Diego, California

PROFESSIONAL PRESENTATIONS

01. A Clinical Case ofPhotopsia -Acute Zonal Occult Outer Retinopathy Ketchum University College of Optometry, Fullerton, California; February 2015

02. The Retinal Detachment Post-Operative Patient Orange County Optometric Society CE Meeting, Orange County, California; February 2015

03. AMD look-a-likes Rio Honda Optometric Society CE Meeting, La Habra, California; February 2015

04. Torpedo Maculopathy Ketchum University College of Optometry, Fullerton, California; May 2015

05. Chorioderemia 1

j~1- = ~ ==-=~==- ---- ~== --------------~-~== -~ If-''

08. Vision loss and Diabetes--------O-GUia6etes resource at St Joe'sneritage healtficare center, Santa Ana, California; Dec20-i-5'---------- 09. Palinopsia

Ketchum University College of Optometry, Fullerton, California; Feb 2016

ACCEPTED POSTERS

01. The use ofMacular Microperimetry in Early Detection ofPlaquenil Toxicity in Addition to OCT, mERG and FAF American Academy of Optometry, New Orleans, Louisana; October 2015

02. Torpedo Maculopathy: In-depth analysis with OCT, MAIA, IVFA, mERG American Academy of Optom'.etry, New Orleans, Louisana; October 2015

CLINICAL RESEARCH EXPERIENCE

01. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD-A), Phase III; 2012-Present Visual Acuity Examiner & Certified Refractionist. A randomized, double-masked, placebo-controlled study of the safety and efficacy ofgevokizumab in the treatment ofactive non-infectious intermediate, posterior, or pan-uveitis

02. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD-C), Phase III; 2012-Present Visual Acuity Examiner & Ce1tified Refractionist. A randomized, double-masked, placebo-controlled study of the safety and efficacy ofgevokizumab in the treatment ofsubjects with non-infectious intermediate, posteri01; or pan- uveitis currently controlled with systemic treatment

03. Ophthotech, Protocol OPH1003 (ECLIPSE), Phase III; 2013-Present Visual Acuity Examiner & Ce1tified Refractionist. A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration ofFovista (Anti-P DGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular macular degeneration

04. Xoma, Protocol X052132 (EYEGUARD-E), Phase III; 2014-Present Visual Acuity Examiner & Ce1tified Refractionist. An open-label, non-randomized, single-arm, roll-over study to continue dosing ofGevokizumab in non-infectious intermediate, posteri01; or pan-uveitis patients who each successjit!ly completed either the X052130 or the X052131 study

-

05. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), P-nase UI;-W-14--Presenf Visual Acuity Examiner & Ce1tified Refractionist. A randomized, double-masked, sham-controlled study to assess the efficacy and safety oflampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration

06. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-Present Visual Acuity Examiner & Ce1tified Refractionist. A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study ofthe efficacy and safety ofintravitreal REGN2176-3 in patients with

72 P(lgc 3 of 5

J=-~ -------------------------------neovascular age-related macular degeneration

07. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-Present Visual Acuity Examiner & Certified Refractionist. A phase 2, randomized, double-masked, multicente1; active-controlled study evaluating administration ofrepeated intravitreal doses ofhl-conl7'M in patients with choroidal neovascularization secondary to age-related macular degeneratibn

08. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present Visual Acuity Examiner & Certified Refractionist. A multicenter, randomized, double-masked, parallelgroup, active-controlled study evaluating the safety and efficacy ofabicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration

09. Ophthotech, Protocol OPH1004 Phase III; 2015-Present Visual Acuity Examiner & Certified Refractionist. A phase 3, randomized, double-masked, controlled tiral to establish the safety and efficacy ofintravitreous administration ofFovista (anit PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

10. Ophthotech, Protocol OPH1006 Phase III; 2015-Present Visual Acuity Examiner & Certified Refractionist. Effect ofanti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study ofAvastin, Lucentis, or Eylea ( anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

11. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-Present Visual Acuity Examiner & Certified Refractionist. A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety ofASP8232 in reducing central retinal thickness in subjects with

diabetic macular edema

CERTIFICATIONS

Paragon CRT for Corneal Refractive Therapy Ce1iified by Paragon in April 2013

CPR Cetiified by NS CPR course Expires 5/8/2016

LEADERSHIP

2015 - Present Sponsorship & Events chair, Orange County Optometric Society Board

February 2015 Orange County Optometric Society Delegate, House of Delegates, San Jose

2013 - 2014 Student Fellow, American Academy of Optometry

2012- 2014 Western U AAO liaison, American Academy of Optometry

73 Pagc4 or5

I

j_ c~== ----'"---------==~~======== --------- -------- -i- ii o .u

,,.1 tr,

Treasurer, Stuclent Government Assoc1atr-011Classof 2014

2012-2014 Trip Coordinato1~ Volunteer Optometric Service to Humanity

2011-2014 Treasurer, National Optometric Student Association

2007-2010 President & Founder, VisualEyes Society (UCSD's Pre-optometry club)

COMMUNITY SERVICE MISSION TRIPS

Feb 2015 Optometrist, Calvary Chapel Mexico Mission trip, Ensenada, Mexico

March 2013 4th year Optometry Student, Volunteer Optometric Services to Humanity (VOSH) Mission trip, San Carlos, Mexico

PROFESSIONAL SOCIETY MEMBERSHIPS

2014 - Present Orange County Optometric Society

2014 - Present California Optometric Association

2014- Present American Academy of Optometry

2011 - Present American Optometric Association

LANGUAGES

Chinese: Cantonese (Fluent), Mandarin (Understand)

74 Page 5 or5

MEI-CHUAN MARGRET YU 5521 Sierra Verde, Irvine, CA 92603

[email protected] I 949.394.1913

EDUCATION

Southern California College of Optometry - Fullerton, CA August 2010 - May 2014 t

Doctor of Optometry

University of California, Irvine - Irvine, CA September 2004 -June 2008 Bachelor of Science in Biological Sciences with honors and cum laude Spanish Minor

University High School - Irvine, CA September 2000-June 2004 High School Diploma, Magna cum laude

CERTIFICATES/LICENSES Paragon CRT Certification (July 2014)

CA State Board of Optometry (June 2014)

NBEO Part I (March 2013), Part II (December 2013), Part Ill (January 2014)

Cardiopulmonary Resuscitation Certified (September 2010 - 2012; March 2013 - 2015)

Bible Truth and Church Service Training (August 2008 -July 2010)

Completion of Regional Occupational Program in AutoCAD (2003)

CLINICAL/PROFESSIONAL EXPERIENCES

July 2015-Present Orange County Retina Medical Group-Laguna Hills, CA

Resident Optometrist - Co-management of referral-based vitreous, macular, and retinal diseases - Assistant preceptor for Western University College of Optometry and Southern California College of

Optometry fourth year students

June 2014-Present Golden Vision Optometry-Irvine, CA

Optometrist - Primary eye care, Cataract/Refractive Surgery Co-Management, Ocular Disease - Paragon CRT, RGP, soft/toric/multifocal contact lens

March -May 2014 Cedars Sinai Vision Center - Beverly Hills, CA

Optometric Intern Primary Eye Care, Ocular Disease, Contact Lens, Pre/Post-Operative Care, Co-Management, Pediatrics

2010-February 2014 Southern California College of Optometry Eye Care Center - Fullerton, CA

Optometric Intern Primary Eye Care, Ocular Disease, Contact Lens, Vision Therapy, Pediatrics

75 1


Special Populations, Low Vision, Special Testing/Electrodiagnostics, Garden Grove Boys and Girls Clinic

August - November 2013 Bakersfield VA Healthcare - Bakersfield, CA Optometric Intern

Primary Eye Care, Ocular Disease

May -August 2013 Hoopes 'lision Institute - Draper, UT Optometric Intern

Pre and Post-Operative Cataract and Refractive Surgery Care, Ocular Disease, Primary Eye Care ICL, lntraLASIK, PRK, RGP/Hybrid contact lenses, Orbscan/Pentacam interpretation

March - May 2013 Caduceus Medical Group: Eyes and Ears - Fullerton, CA Optometric Intern

Primary Eye Care, Ocular Disease, Contact Lens

2004-2008 Lowell J. Booth Optometry-Tustin, CA Optometric A

Documents

Clinical Pearls for Retinal Surgery